Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.09% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.19 | 52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3442.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -161.01% | Return on Equity (TTM) -694.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5064418 | Price to Sales(TTM) - |
Enterprise Value -5064418 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 567456 | Shares Floating 428235 |
Shares Outstanding 567456 | Shares Floating 428235 | ||
Percent Insiders 8.84 | Percent Institutions 1.27 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack Inc. (formerly known as Integrity Applications Inc.) was founded in 2003. It focused on developing and commercializing non-invasive glucose monitoring technology. The company's history has been marked by product development challenges and regulatory hurdles.
Core Business Areas
- Non-invasive Glucose Monitoring: GlucoTrack's core business revolves around the development, manufacturing, and commercialization of the GlucoTracku00ae Model DF-F non-invasive blood glucose monitoring device.
Leadership and Structure
Details regarding current leadership and organizational structure are limited in public information. The company has undergone several leadership changes over the years.
Top Products and Market Share
Key Offerings
- GlucoTracku00ae Model DF-F: The GlucoTracku00ae Model DF-F is a non-invasive glucose monitoring device designed for people with type 2 diabetes who are not on insulin. The device measures glucose levels using a combination of ultrasonic, electromagnetic and thermal technologies. It is not widely adopted, and market share data is not readily available. Competitors include traditional blood glucose meters from companies like Abbott (ABT) and Dexcom (DXCM), as well as continuous glucose monitors (CGMs).
Market Dynamics
Industry Overview
The diabetes monitoring market is a large and growing market, driven by the increasing prevalence of diabetes globally. Key trends include the adoption of continuous glucose monitors (CGMs), connected devices, and telehealth solutions.
Positioning
GlucoTrack is positioned as a non-invasive alternative to traditional blood glucose meters and CGMs. However, the company has faced challenges in gaining market share due to product performance and regulatory issues.
Total Addressable Market (TAM)
The global diabetes monitoring market is estimated to be worth tens of billions of dollars annually. GlucoTrack's potential market share is limited by its product's capabilities and regulatory approvals. The company is trying to get approval in many countries.
Upturn SWOT Analysis
Strengths
- Non-invasive technology (potential appeal)
- Potential for improved patient compliance
Weaknesses
- Limited clinical data supporting accuracy
- Regulatory challenges
- Limited market adoption
- Historical financial instability
Opportunities
- Partnerships with diabetes management companies
- Expansion into new markets
- Development of next-generation non-invasive technologies
- Increased awareness of non-invasive glucose monitoring
Threats
- Competition from established players (Abbott, Dexcom)
- Technological advancements in CGMs
- Changing regulatory landscape
- Negative publicity regarding product performance
Competitors and Market Share
Key Competitors
- ABT
- DXCM
Competitive Landscape
GlucoTrack faces significant disadvantages compared to established players like Abbott and Dexcom, which have superior products, larger market share, and stronger financial resources.
Growth Trajectory and Initiatives
Historical Growth: GlucoTrack's growth has been limited by product performance, regulatory issues, and competition.
Future Projections: Future projections are highly uncertain, dependent on regulatory approvals and market acceptance of its technology.
Recent Initiatives: Recent initiatives include attempts to gain regulatory approval in new markets and improve product performance.
Summary
GlucoTrack's non-invasive technology holds potential, but faces challenges in accuracy, regulatory approval, and market competition. The company's historical financial instability poses a significant risk. Success depends on improvements in product performance, successful navigation of regulatory hurdles, and strategic partnerships. Without these improvements, GlucoTrack is in a very risky situation. The company needs to watch out for larger companies taking their spot.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is subject to change without notice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 11 | Website https://glucotrack.com |
Full time employees 11 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.